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Abnormal blood clot stiffness is an important indicator of coagulation disorders arising from a variety
of cardiovascular diseases and drug treatments. Here, we present a portable instrument for elastometry
of microliter volume blood samples based upon the principle of resonant acoustic spectroscopy, where
a sample of well-defined dimensions exhibits a fundamental longitudinal resonance mode propor-
tional to the square root of the Young’s modulus. In contrast to commercial thromboelastography, the
resonant acoustic method offers improved repeatability and accuracy due to the high signal-to-noise
ratio of the resonant vibration. We review the measurement principles and the design of a magnetically
actuated microbead force transducer applying between 23 pN and 6.7 nN, providing a wide dynamic
range of elastic moduli (3 Pa–27 kPa) appropriate for measurement of clot elastic modulus (CEM). An
automated and portable device, the CEMport, is introduced and implemented using a 2 nm resolution
displacement sensor with demonstrated accuracy and precision of 3% and 2%, respectively, of CEM
in biogels. Importantly, the small strains (<0.13%) and low strain rates (<1/s) employed by the
CEMport maintain a linear stress-to-strain relationship which provides a perturbative measurement
of the Young’s modulus. Measurements of blood plasma CEM versus heparin concentration show
that CEMport is sensitive to heparin levels below 0.050 U/ml, which suggests future applications
in sensing heparin levels of post-surgical cardiopulmonary bypass patients. The portability, high
accuracy, and high precision of this device enable new clinical and animal studies for associating
CEM with blood coagulation disorders, potentially leading to improved diagnostics and therapeutic
monitoring. C 2015 AIP Publishing LLC. [http://dx.doi.org/10.1063/1.4926543]
I. INTRODUCTION
A. Motivation
Abnormal structure and mechanical properties of blood
clots are associated with cardiovascular disorders such as coro-
nary artery disease (CAD),1 myocardial infarction (MI),2 dia-
betes,3,4 and multiple myeloma.5 In particular, clot stiffness,
i.e., clot elastic modulus (CEM), has recently emerged as a
tool for understanding hemostasis and classifying a variety of
cardiovascular diseases (CVDs) and coagulopathies. CEM is
dictated by the mechanical properties and available quantity
of its constituent proteins and blood cells such as fibrin, plate-
lets, and erythrocytes in a given pathological state. Interest-
ingly, abnormal fibrin fiber thickness, density, and resistance to
clot degradation (fibrinolysis) have each been associated with
thromboembolic diseases and bleeding disorders.6–8 Similarly,
abnormal fibrinolysis and reduced clot strength have also been
shown to be significant indicators of mortality rates in severe
trauma.9 Thus, CEM provides direct insight into blood clot
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structure, which offers the potential to impact both our under-
standing of coagulation disorders and the surgical manage-
ment of hemostasis. This work presents a portable micro-
elastometry device for highly accurate measurements of CEM.
The use of microliter blood volumes enables its application
toward research using small animal models, while the compact
size and portability of the instrument have the potential to
enable new translational studies in a clinical setting.
From a clinical perspective, the immediate importance
of such a device rests in its ability to provide accurate and
repeatable diagnostic information about clot structure and clot
formation during surgery. In 2010, there was one death every
40 s in the USA as a result of CVD,10 and many of these
patients required surgical intervention. At present, cardiopul-
monary bypass and heart transplant surgeries employ the use
of dose dependent heparin anticoagulation to avoid throm-
boembolic events secondary to clot formation. Maintaining
an appropriate level of anticoagulation during surgery while
reversing the effects of heparin after surgery is critical for
reducing patient complications such as postoperative bleed-
ing. Heparin management, however, is still largely determined
by activated coagulation time (ACT), a method with poor
sensitivity and lack of correlation with heparin post-surgical
rebound, while physical measures using thromboelastography
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(TEG) have indicated higher sensitivity.11–13 To illustrate the
clinical significance of CEM and its potential relevance in
managing surgical hemostasis, here we demonstrate the sensi-
tivity of our device to varying plasma levels of heparin.
B. Clot elastometry
Blood clots offer particular challenges to mechanical
analysis. For example, biological factors such as platelet ac-
tivity and coagulation rate induce time-dependent changes,
while factors within a mechanical measurement apparatus,
such as strain amplitude and strain rate, can induce vari-
ability in the resulting measurements. Measuring the CEM
(Young’s modulus) fundamentally requires instrument sensi-
tivity to longitudinal stress (force) and strain (displacement).
In contrast to mechanical analyzers used for structural mate-
rials, the inherent softness (CEM <5 kPa) of blood and plasma
requires an instrument with particularly delicate force and
displacement sensitivity. At the same time, microliter sam-
ple volumes afford researchers the ability to perform fewer
replicate sample blood collections and parallel analysis with
remaining sample volumes more amenable to animal research.
One of the most prevalent commercial clot mechanical an-
alyzers is the TEG, which provides measurements of the
clot reaction time, rate of clot formation, and clot strength.
However, to date, TEG lacks standardization and has limited
repeatability and diagnostic sensitivity.14 TEG and related
instruments, such as ROTEM and Hemodyne, are types of
shear rheometers, where a cup containing the sample is moved
relative to a pin or cone inserted into the sample to measure
shear stress under controlled shear strain.5,15 Research-based
shear rheometers are also commonly used for characterizing
CEM as a function of both strain amplitude and frequency.16,17
Typically, these types of measurements employ relatively large
strain in order to produce adequate stress for detection, which
can induce non-linearity in the stress-strain response; blood
clots, in particular, are known to be strain-stiffening.18
To improve the force sensitivity, cantilevers are often
used, such as in atomic force microscopy (AFM). While AFM
has found utility in describing the mechanical properties of
individual fibrin fibers,19 the ability to measure the bulk clot
properties requires a larger surface area of contact, a non-
ideal condition on a standard AFM instrument. Recently, a
cantilever was developed specifically for soft material analysis
and validated in biogels,20 although it remains to be demon-
strated in materials with elastic moduli <1 kPa, such as that
of blood plasma. Another promising strategy is the use of a
torsion pendulum with which the free oscillations are recorded
in response to release of a shear stress,21 a method employed
with success for characterizing the viscoelasticity of blood
clots.1 The torsion pendulum shares some similarities with the
technique described in this paper, resonant acoustic spectros-
copy with optical vibrometry (RASOV), as will be discussed
below.
C. Clot micro-elastometry using RASOV
The use of a system resonance to provide a strong signal-
to-noise ratio (SNR) for measurement is a long-utilized
technique for the development of instruments. In the field of
elastometry, the shift in resonance of a high-Q cantilever has
been shown as an accurate method for measuring thin films in
the gigaPascal range.22 Similarly, shifts in the frequency of a
quartz crystal have been used to study coagulation by semi-
quantification of the viscoelastic mass.23 Instead of using a
separate resonating material, in the technique called resonant
ultrasound spectroscopy (RUS), one measures the mechanical
resonance spectrum of the sample directly, and knowing the
sample geometry, the components of the elastic tensor can
be inferred.24 While RUS is employed to characterize stiff
materials, it was found that soft biogels and tissues exhibit
resonances with sufficiently high Q (∼3) to enable mechanical
analysis.25 For simplicity, one assumes the tissue is mechan-
ically isotropic in order to extract a single value of elastic
modulus from the observed fundamental longitudinal mode.
These resonances typically occur in the acoustic (Hz-kHz)
range due to the softness of the materials. Recently, some of
the co-authors developed this method into a blood elastometer
where a blood sample is allowed to clot in a microwell,
and a microbead transducer placed atop the sample is subse-
quently frequency-swept, while an optical system was used
to detect the microbead; this was dubbed RASOV.26 RASOV
was shown to provide improved repeatability relative to TEG
when analyzing whole blood samples; the improvements are
attributed to the use of acoustic resonances, a fixed geometry
microwell with closed-boundaries, low actuator inertia, and
minimal actuation forces.27 Interestingly, using the resonance
frequency to infer elastic modulus is physically the same as
using the free oscillation frequency via the torsion pendulum;
however, the SNR of the resonance measurement is able to
be arbitrarily improved by using a slower frequency sweep,
whereas the free oscillation signal is limited in SNR by the
damping rate which shortens the available measurement time
window.
In this paper, we report the construction of a RASOV sys-
tem tailored for CEM measurement that is compact, portable,
and automated, called “CEMport,” to enable future clinical
studies. Importantly, this instrument offers improved displace-
ment resolution via a compact commercial displacement
sensor to increase the dynamic range. As will be shown, this
has allowed us to fully characterize the range of strains in
the CEMport that provides accurate measurements of CEM
within the linear viscoelastic regime. Below, we begin by re-
viewing the measurement principles of RASOV and lay out the
quantitative design metrics that are used to optimally design
CEMport for analysis of blood and plasma samples. After
calibration and characterization of the device performance,
we perform a study in human plasma samples spiked with
heparin to investigate the potential application of the CEMport
for aiding in heparin management.
II. METHODS
A. Measurement principle
In this section, we discuss the physical model and method
of RASOV for elasticity measurement. RASOV measures the
linear, isotropic elastic modulus of soft biological gels and
075005-3 Krebs et al. Rev. Sci. Instrum. 86, 075005 (2015)
clots of controlled size by preparing them within a microw-
ell. The linearity of the elasticity measurement is ensured by
inducing a small uniaxial strain to the specimen; evidence that
the strain is sufficiently small will be presented in Section III.
Under this operational condition, the sample can be viewed as
a linear-shift-invariant (LSI) system. The concept of the im-
pulse response of a LSI system is then used to extract mechan-
ical properties of the specimen.28 Following linear elastic the-
ory,29 the elastic modulus of an elastically isotropic specimen
of known size and boundary conditions can be expressed in
terms of the fundamental resonant frequency of the longitu-
dinal vibration,25,26
E = a0ρ f 20 , (1)
where E is the CEM, ρ is sample mass density, f0 is the
fundamental resonant frequency, and a0 is an experimentally
determined calibration coefficient that depends on the spec-
imen’s geometry, boundary conditions, and Poisson’s ratio.
In order to measure f0, RASOV involves applying a
chirped (frequency-swept), sinusoidal driving force to the
sample, F(t), and the system impulse response is inferred
from the measured displacement, ∆z. First, let us consider the
steady-state solution for a driving force at fixed frequency, ω.
The resultant displacement can be modeled assuming linear
viscous damping and elasticity according to the driven,
damped, harmonic oscillator model,30
∆z′′ (t) + γ0∆z′ (t) + ω20∆z (t) = q ∝ F (t) , (2)
where q is proportional to the driving force, ω is the angular
frequency of the driving force waveform, and γ0 and ω0
= 2π f0 are the damping coefficient and natural angular fre-
quency for the fundamental vibration mode, respectively,
where f0 is the corresponding natural frequency. For a com-
plex driving force waveform, F̃(t) = F(t)eiωt, the complex
displacement solution can be written as
∆z̃(t) = Ã(ω)eiωt, (3)
where the amplitude is described by a complex Lorentzian
function
Ã(ω) = q
ω20 − ω2 + iωγ0
. (4)
In a RASOV measurement where F̃(t) is a chirped sinu-
soidal waveform, the mechanical system response, Ĩ(ω), is
characterized by the frequency-domain transfer function of the
LSI system as follows:
Ĩ (ω) = Φ [∆z(t)]
Φ [F(t)] ∝ Ã(ω), (5)
where Φ is the Fourier transform operator. The magnitude
of Ĩ(ω) represents the magnitude of the vibration, while the
argument represents the phase difference between the vibra-
tion waveform (strain) and the driving force waveform (stress).
Importantly, the Lorentzian solution predicts a phase transition
from 0 to π across the fundamental resonance mode, which
indicates a transition from stress and strain being in-phase
to being exactly opposed.25 An example of this phenomenon
from a RASOV measurement of a plasma sample is shown in
Fig. 1. The fundamental natural frequency f0 is thus obtained
FIG. 1. Example data set showing the (a) magnitude and (b) phase of Ĩ(ω)
obtained from a RASOV measurement of normal platelet-poor plasma (NPP).
by fitting the magnitude and/or phase of Ĩ(ω) to the Lorentzian
solution, Eq. (4), and the corresponding CEM is then derived
using Eq. (1). The data processing procedure is deferred to
Subsection II F. Importantly, this measurement of CEM repre-
sents the storage modulus at the strain rate dictated by the
resonance frequency; RASOV does not provide frequency-
dependent elastic properties. As discussed below, we do not
expect CEM to be significantly frequency-dependent in the
regime of strain rates applied by RASOV but rather to repre-
sent the low strain rate (perturbative) value.
B. The microbead transducer
In the CEMport, the driving force is provided by magneti-
cally actuating a steel microbead transducer on top of the spec-
imen via a solenoid electromagnet positioned underneath the
specimen (Fig. 2). An important factor when choosing a mi-
crobead transducer is its inertial mass. It has been shown that
heavier transducers will lower the observed resonant frequen-
cies.31 In the other extreme, magnetic nanoparticles can be
embedded into the sample for transduction;25 however, these
have been found to interfere with clotting processes for CEM
measurement. In the CEMport, a chrome steel microbead of
0.7 mg and 500 µm diameter (grade 25, Salem ball company)
is chosen as the transducer by merit that it is large enough to
handle with tweezers and to provide sufficiently large magnetic
gradient force but light enough to limit its perturbation to the
resonance of the specimen. Within an externally applied mag-
netic field, the intensity and direction of the transduction force
are determined by the magnetic properties of the microbead
and shape of the local magnetic field lines, respectively. The
microbead is pulled in ẑ (vertically) by the electromagnet via
the coupling between its induced magnetic dipole moment,
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FIG. 2. (a) Schematic of the signal and device components of the CEMport. (b) An enlarged view schematic of the sample microwell. Insets display photographs
of the 500 µm bead (small red arrow) and the sample microwell. (c) Photographs of the CEMport with major components indicated. Left: overall view of the
portable cart. Right: layout within the humidified chamber. Blood clots prepared within the plastic microwell are slid into a plastic mount; the use of plastic
avoids induced currents during operation of the solenoid electromagnet. A small air gap and vibration-damped mounting post ensure that the microwell and
displacement sensor are mechanically isolated from the solenoid during RASOV.
m, and the external magnetic field, B. The induced dipole
moment is linear in B for small applied fields. The B field is
proportional to the solenoid current, which is proportional to
the driving voltage V at the frequencies used in this system
where inductance is negligible. Thus, the force waveform is
proportional to the square of the voltage driving the electro-
magnet,
F (t) = (m · ∇)B ∝ (B · ∇)B ∝ V (t)2ẑ (6)
where the coefficient of proportionality is dependent on the
magnetic susceptibility and volume of microbead, its sepa-
ration from the solenoid, and the properties of the solenoid
(turn density and electrical resistance). The direction of the
force is along the ẑ axis when the mircobead is properly placed
within the central axis of the solenoid winding; furthermore,
the sample holder is aligned with the solenoid so that the
resulting transduced force is applied normal to the specimen
surface and at its center (Fig. 2(b)). This alignment is important
to avoid possible shear strains in x̂ and ŷ that induce torsional
vibrational modes instead of the desired longitudinal modes,
which complicate the resonant acoustic spectral analysis.
Importantly, the microbead transducer is designed to
deliver a relevant range of forces for accurate measurement
of CEM. Let us define the magnetic gradient force according
to Eq. (6) as (B · ∇)B, which has units of T2/m. The magnetic
gradient force was measured via a Hall probe in the ẑ direction
at 2.0 cm above the surface of the coil and was found to range
from (6.0 × 10−5–1.78 × 10−2) T2/m over the (0.25–10.0) Vpp
range of the waveform generator. Estimating the volume mag-
netic susceptibility of the chrome steel microbead as 0.72
× 10−2 and using the known volume of the bead, the transduc-
tion force of the RASOV system is computed to be within the
range of (22.5 pN–6.68 nN). Now, let us consider whether this
range provides sufficient flexibility to accurately measure the
CEM of blood samples. As shown in Section III, the optimal
range of indentation amplitudes for accurate measurement in
the RASOV system is (740 nm–7.5 µm) at resonance. This
represents a dynamic amplitude, which can be related to a cor-
responding quasi-static indentation amplitude by dividing by
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the quality factor, Q = ω0/γ0, which is typically ≈15 for blood
samples. Finally, we use the Hertz model of contact mechanics
to relate the CEM, the quasi-static indentation amplitude, and
the force applied by the microbead of known diameter.32 If
we consider the minimum CEM to be that obtained with the
minimum available transduction force and maximum measur-
able indentation, and the maximum CEM to be that with
the maximum force and minimum indentation, we obtain a
dynamic range of the CEMport system of (3 Pa–27 kPa).
This dynamic range is broad enough to cover the typical
elasticity range of whole blood clots (∼1.5 kPa–5 kPa),26
plasma (∼0.3 kPa–2 kPa),33 and other materials with elastic
moduli within this range.
C. Instrument design
The CEMport is a portable blood clot micro-elastometry
instrument consisting of a laser displacement sensor, sam-
ple microwell, microbead transducer, solenoid electromagnet,
motorized stages, sampling hardware, and LabVIEW-driven
graphic user interface (GUI) (see Fig. 2). The solenoid is
powered by a programmable 250 Watt power supply (KEPCO,
Model ATE 36-8) which is modulated with a square-root
sinusoidal, chirped voltage waveform (described in D below)
via an arbitrary function generator (Agilent Technologies,
Model 33522A). At present, the power supply is operated at
1/3rd of its capacity to reserve extra electrical power for the
addition of two future solenoids. The solenoid coil consists
of 18-American wire gauge (AWG), poly-thermaleze coated
magnet wire (Allied Electronics) wrapped around a custom-
machined Ultem (McMaster Carr) bobbin in ∼26 total layers
and held in place with a thermally conductive and electrically
insulating adhesive (Cast-Coat, Inc, CC3-301 AD). It was
wound around the Ultem bobbin spindle with the following
dimensions: 10 cm (outer diameter), 1.5 cm (height), and
1 cm (inner diameter). These dimensions were optimized via
computational simulations to maximize the magnetic gradient
force while achieving a compact prototype design ideal for
portability. To avoid the need for water cooling, which would
add unwanted bulk to the device, an automated triggering
mechanism limits the electrical current through the coil to
short-burst sampling intervals. To maintain a strong magnetic
gradient force, a minimal gap between the solenoid and the
microwell stage was maintained. At the same time, the mag-
net was mechanically decoupled from the stage to prevent
vibrations induced within the magnet from directly shaking
the microwell.
Displacement measurements were obtained with a
commercial laser displacement sensor (Keyence, LK-H008)
which delivers a 0.3 mW, 655 nm wavelength, and 20 µm
spot size that is reflected from the surface of the bead. The
laser is coupled to an associated controller (Keyence, LK-
G5001) for triangulating the return trajectory of the beam
via a RS-CMOS element. The displacement detection range
and resolution were set to 20 µm and 2 nm, respectively, via
the device software. Additionally, a low-pass, 1000 Hz filter
setting was chosen on the controller to improve the signal-to-
noise ratio at the lower frequencies relevant to the acoustic
resonances in our experiments.
D. Instrument operation
In the CEMport, the procedure for RASOV measure-
ment of a sample clotted within the microwell includes the
steps of microbead placement, sample rate selection, peak-
to-peak driving voltage selection, and maximum sweep fre-
quency selection. Once these parameters are chosen by the
user within the custom GUI (National Instruments, LabVIEW
2012), a series of discrete sampling scans occur to align the
microbead with the displacement sensor laser prior to the
acoustic scan.
The custom GUI was programmed to coordinate sam-
ple stage positioning, electromagnet waveform generation,
displacement data acquisition, and subsequent data analysis.
This offered a user-friendly interface for selecting the sampling
rate (1–2 kS/s), waveform voltage amplitude (0.25–10.0 Vpp),
and maximum sweep frequency (75–1000 Hz) prior to data
acquisition. Immediately before a scan, the user sends a ze-
roing command to the displacement sensor to ensure the
maximum available dynamic range of vibrations above and
below the equilibrium position of the microbead. When initi-
ating a scan, the GUI simultaneously signals the laser displace-
ment sensor to collect data, signals the waveform generator to
burst a pre-loaded waveform, and reads in the displacement
data from a digitizer (National Instruments, USB-6009) con-
nected to the displacement controller’s analog output
terminals.
Accurate data collection requires precise alignment of the
microbead such that the laser reflects off the center of the
bead. To automate this alignment process, the displacement
sensor was mounted to a 3-axis motorized stage (Thor Labs,
MT3-Z8) with associated controllers (Thor Labs, TDC001 T-
Cube DC Servo) connected with the LabVIEW interface. The
interface enables a 3D scan of the laser by rastering within a
1.5 mm× 1.5 mm x-y plane over 100× 100 µm steps to locate
the bead, incrementally dropping by 100 µm steps in z until
bead recognition occurs. Scan times are typically 90 s after
placement of a new sample, while successive measurements
of the same sample only require a few seconds for realignment
due to sample dehydration during data acquisition.
Finally, due to the high-water content of biosamples and
the negative impact of sample dehydration on the assessment
of CEM, a sealed, humidified chamber was constructed from
acrylic panels and anodized structural beams (Makerbeam).
The use of a humidified chamber provided a significant reduc-
tion in the sample dehydration rate, which was reduced from
245 nm/s to 81 nm/s for a 3 mg/ml agarose sample in the
open air compared to an 85% humidified environment, respec-
tively. Humidity control was accomplished through the use
of a positive-feedback loop and a humidity sensor (AGPtek
Digital Air Humidity Controller, model WH8040) wired to an
electrical relay, which provided power to an off-the-shelf room
humidifier (Holmes Ultrasonic Humidifier, model HM500TG)
connected to the sealed chamber via rubber tubing.
E. Sample preparation and data collection
For RASOV, samples are prepared within fixed dimension
microwells (5 mm (l) × 5 mm (w) × 6 mm (d)) corresponding
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to a volume of 150 µL. The gelation microwell was 3-D printed
from VeroBlue (RGD840), rigid, opaque photopolymer (Poly-
Jet, Stratasys, Eden Prairie, MN). For instrument calibration
and strain sensitivity measurements, agarose powder (Sigma-
Aldrich #A0169, Type I-A, low EEO) was added to distilled
water with varying concentrations (3–10 mg/ml) and was
heated in a hot water bath (85 ◦C) for 20 min. Solutions were
pipetted into microwells where they were allowed to cool at
room temperature for at least 30 min within a sealed, humid-
ified chamber. CEMport calibration data were then acquired
within 210 min after preparation from 2 agarose samples at
each concentration, collecting 10-30 consecutive measure-
ments per sample. Additionally, 10 consecutive measurements
per sample were collected for strain sensitivity data using a
fresh agarose sample for each strain value to avoid ambiguity
from sample dehydration.
Plasma samples of varying heparin concentrations were
prepared in the CEMport microwells as follows. Pooled NPP
was prepared from healthy human volunteers according to a
protocol approved by the University of North Carolina Insti-
tutional Review Board, as described.34 Stock heparin sodium
(1 U/µL, APP Fresenius Kabi USA, LLC) was prepared at
varying concentrations into buffer (150 mM NaCl and 96 mM
benzyl alcohol). Samples were prepared by pipetting 10 µl
calcium (150 mM stock solution), 10 µl diluted heparin or
control buffer, and 25 µL tissue factor/lipids (Stago BNL,
6 pM/24 µM) into separate corners of the microwell; NPP
(105 µL) was added as the final mixing step for the sample.
This procedure resulted in final concentrations of 10 mM
calcium, 0–0.27 U/ml heparin, and 1 pM/4 µM tissue fac-
tor/lipids. Samples were allowed to clot for 2-3 h before they
were measured by RASOV. RASOV data were then acquired
from 1 to 2 samples at each concentration, collecting 10-30
consecutive measurements per sample.
F. Signal processing
Here, we describe the signal processing steps used in the
CEMport to convert the measured displacement signal into an
estimate of f0 according to Eqs. (4) and (5). We found that




Ã(ω) was less error-prone than




Ã(ω). For ultralow strain
displacement signals, the phase shift from 0 toπ at resonance is
particularly distinct and is specific to induced modulations that
are phase-locked to the transducer, rejecting randomly phased
noise. To measure the acoustic resonance spectrum, the elec-
tromagnet voltage waveform was frequency-swept (chirped),
V (t) ∝

1 − cos (πkt2)
2
, (7)
where k is the linear chirp rate determined by the frequency
sweep range (0–(300-1000)Hz) and the duration (2 s) of the
scan. According to Eq. (6), the resulting force waveform is thus






This force waveform is used to calculate the frequency-domain
transfer function, Ĩ(ω), according to Eq. (5), which is propor-
tional to the complex specimen vibration, Ã(ω). The data
analysis script, an essential part of the instrument, employs








Ã(ω) LSF→ tan−1 γ0ω
ω20 − ω2
+ βω, (10)
where q, ω0, and γ0 are free-fit parameters. The term βω in
Eq. (10) is added to account for imperfect synchronization
between the waveform generator burst and the displacement
sensor measurement. β represents the time lag between these
events, which is up to ±10 ms in our system. (A constant offset
in time, after Fourier transformation, becomes a linear phase
ramp in frequency.)
A semi-automated fitting routine was developed to pro-
vide an objective measurement of f0 based upon RASOV data.
The only input from the user is the frequency range over which
to fit data, after which four steps are performed to robustly
converge on the best-fit f0. These steps are detailed in Table I.
Amplitude data are first fitted to obtain a rough estimate of f0
(step 1), while phase data in the frequency spectral range below
the resonance are fitted to a straight line to obtain an estimate
of the phase ramp, β (step 2). These two preliminary steps are
used to pre-condition the phase data (by subtracting the phase
ramp) and to provide initial guesses for a LSF of the phase data
(step 3). Because of the relatively high dimensionality of the
fitting (ω0, γ0, and β all being free-fit parameters), we found
that an additional step is required to avoid a LSF convergence
toward a possible local minimum. Thus, step 4 consists of
incrementing the initial guess for β and obtaining the global
minimum over all of the increments. Final phase fitting results
are only retained when the corresponding coefficient of deter-
mination (R2) is above 0.85.
III. RESULTS AND DISCUSSION
A. Strain sensitivity
Compared to the previous RASOV instrument,26 the
CEMport offers improved displacement sensitivity (from 6 nm
to 2 nm) and improved maximum displacement (from 300 nm
to 7510 nm) by switching from an optical imaging system (op-
tical coherence tomography (OCT)) to a commercial displace-
ment sensor (Keyence). Thus, CEMport effectively increases
the available dynamic range of displacement from 50× to
3750×. These improvements have led to a larger window of
transduction forces that provide an accurate measurement of
CEM. Here, we characterize the strain dynamic range over
which accurate measurements of CEM are obtained by the
CEMport.
The dynamic range of peak-to-peak resonant displace-
ment amplitudes over which the resonant frequency, f0, is
insensitive to the value of the strain is an important figure of
merit of the CEMport. For strains that are too large, the sample
is no longer linearly viscoelastic. For strains that are too small,
the system noise is too great to obtain an accurate data fitting.
Since the user will typically measure samples with unknown
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TABLE I. Method for semi-automated fitting of RASOV data with the CEMport.
Data range Fitting parameters
Step Data (low↔ high) FFPa → IGb → (LB–UB)c Model
1 Amplitude User-definedd
ω01 → autoe → (0– fmax)f
Amplitude (Eq. (9))γ01 → auto → (0–0.5 fmax)
p01 → auto → (0–1.5Ipeak)g
2 Phase (unwrapped) (ω01−γ01)2 ↔ (ω01−γ01) β2 → 0 → unbounded φramp= β2ω
3 Phase minus φramp
ω01
5 ↔ fmax
ω03 → ω01 → (0− fmax)
Phase (Eq. (10)), βtot= β2+β3γ03 → γ01 → (0–0.5 fmax)
β3 → 0 → (±50 ms)
4 Phase minus βtotω (ω03−γ03)↔ (ω03+γ03)
ω04 → ω03h → (0− fmax)
Phase (Eq. (10))γ04 → γ03h → (0–0.5 fmax)
β4 → incrementedi → (±50 ms)
aFFP: free-fit parameter (ω: resonant frequency, γ: damping factor, and p: amplitude peak intensity).
bIG: initial guess for subsequent fitting.
cLower (LB) and upper bound (UB) constraints for fitting parameters.
dThe user initially defines a data range covering the fundamental resonance peak.
eThe initial guesses for step 1 are determined automatically by peak-searching.
f fmax is the maximum frequency of the driving force waveform.
gIpeak is the maximum amplitude determined automatically by peak-searching.
hFinal values of ω04 and γ04 are determined from the global minimum of multiple fits obtained while varying IG of β4.
i IG of β4 is incremented around a value of 0 to avoid local minima.
CEM and thus unknown peak amplitude, it is important to
rapidly identify whether a given measurement is within this
dynamic range. If needed, the driving voltage can be adjusted
to achieve a measurement within this target.
Fig. 3(a) shows CEMport displacement data and associ-
ated amplitude and phase fittings with varying driving voltages
to investigate the effect of strain. For this experiment, the
samples consisted of agarose at a concentration of 3.36 mg/ml,
which has an elastic modulus of 3.8 kPa. This is similar
to the elastic modulus of whole blood clots, which exhibit
CEM typically from 1.5 to 5 kPa.26 Fig. 3(b) shows evidence
that the fitted values of f0 are within one standard deviation
for strain amplitudes of 1.23 × 10−4 and 1.25 × 10−3 (n = 10
each), where the corresponding sample surface peak-to-peak
displacements are 739 ± 24 nm and 7510 ± 730 nm, respec-
tively. Two additional measurements obtained at 2.34 × 10−4
and 1.66 × 10−3 (n = 2 each) suggest that there is a plateau
region over which f0 is consistent within experimental error.
At strains below and above this range, f0 is significantly
lowered from the ideal value and the semi-automated LSF
routine is unable to obtain a sufficiently good fit for all 10 data
scans. At the lowest strain measured, the low signal-to-noise
ratio results in poor data fitting. At the highest strain measured,
the data begin to deviate from the linear viscoelastic model,
where the peak at approximately 1/2 f0 suggests nonlinearity in
the mechanical response. Thus, we estimate that the dynamic
range of the peak-to-peak strain amplitude in the CEMport is
1.23 × 10−4–1.25 × 10−3.
Given this result, it is important to address whether the
maximum strain and strain rates employed by the CEMport are
expected to lie within the linear viscoelastic regime of blood
clots and the agarose calibration samples. The mechanical
properties of blood clots are largely dictated by that of their
fibrin network.35 Mechanical measurements of fibrin both in
bulk and on individual molecules show that a linear strain-
stress relation holds for strains well above 1%,17,36 which is
significantly larger than the strain encountered during RASOV
measurements. Frequency-dependent measurements of the
shear modulus for fibrin clots suggest that the storage modulus
is relatively constant for strain rates up to ∼2/s.17 In compar-
ison, a typical blood clot of 4 kPa with resonance at 237 Hz
would have a strain rate between 0.1/s and 1.0/s over the strain
dynamic range of the CEMport. Thus, while smaller strains are
more desirable to avoid potential nonlinearities, the CEMport
is expected to provide consistent measurements of blood clots
over its dynamic range of applied strains. Furthermore, the
smaller resonant frequencies of plasma (as will be shown
below) will have even lower strain rates and further relax this
requirement. Similarly, it has been shown that agarose is highly
linear for strains exceeding 1%,37 while strain rates below∼3/s
exhibit relatively constant shear moduli.38 This observation
suggests that for the maximum concentration agarose sample
used in this study, with a resonance of ∼600 Hz, it would
be important to use a strain amplitude less than 8 × 10−4,
which is still well above the minimum peak-to-peak strain
of 1.23 × 10−4. Lower concentrations of agarose with lower
resonant frequencies will relax this requirement. Overall, these
results suggest that the perturbative nature of the CEMport is
relevant for probing the small-strain, linear elastic moduli of
blood and related biogels.
B. Device calibration
The value of the CEMport lies in its ability to profile
acoustic resonances and to convert these values into calcu-
lated elastic modulus readings using Eq. (1). To calibrate the
CEMport, we use agarose gel because it is easily prepared
in both large and small sample sizes. The elastic modulus of
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FIG. 3. CEMport measurements of agarose samples with varying maximum strain amplitudes by adjusting the solenoid voltage. (a) Top: raw displacement data
versus time; bottom: corresponding amplitude and phase spectral data and their fitting to the Lorentzian model. (b) Fitted f0 versus maximum strain amplitude.
The number of successful fits is indicated for each data point (e.g., 4/10 means 4 out of 10), where only data with R2 > 0.85 are considered successful.
agarose versus concentration can then be accurately measured
via a commercial texture analyzer (using large samples) and
related to RASOV measurements of resonant frequency over
the same concentration range. Fig. 4 shows the calibration of
the CEMport using agarose that has a known concentration-
dependent elastic modulus according to texture analyzer data
collected in our lab previously.26 Similar to other reports, we
have found that the concentration-dependent Young’s modulus
of agarose is consistent with a power-law of 2,37 while we
have introduced an offset concentration, c0, to represent the
threshold value below which a gel does not form. The best-fit
line reported in Fig. 4(a) is slightly different than that in Ref. 18
due to a different value of c0 obtained from the RASOV data
with which the texture analyzer data were subsequently fitted.
CEMport data collected across the same agarose concen-
tration range suggest a linear relationship between concen-
tration and resonant frequency (Fig. 4(b)). Combining the
model fittings from the texture analyzer and the CEMport, the
FIG. 4. Calibration of RASOV using agarose gels of varying concentrations. (a) Elastic moduli measured by a texture analyzer were fitted to a power-law
function.26 (b) Resonant frequencies measured by RASOV were fitted to a linear function. The functional description of RASOV’s characteristic is obtained by
combining the two modeling fittings (mean ± standard deviation).
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where a1 and a2 are coefficients from fitting elastic moduli
obtained by the texture analyzer and resonant frequencies
obtained by the CEMport, respectively. Importantly, this cali-
bration constant is consistent with that from a previous study
(0.076 ± 0.003 Pa/Hz2) in which a microwell of the same
dimensions was used, but where RASOV was performed via
an OCT system.26 Compared to the CEMport described here,
while OCT provided the ability to image the bead sitting on
the sample, it is considerably more bulky, expensive, and not
specifically designed for elastometry. The CEMport provides
a portable and streamlined system for accurate and repeatable
elastometry of blood samples.
In order to measure the CEM of an arbitrary sample, one
must account for differences in the mass density of the sample,
ρ, from that of the agarose used for calibration, according to
Eq. (1). For example, when analyzing whole blood samples,
this requires a small correction. Given that the density of
agarose used to calibrate the CEMport is 1.0 g/ml, we thus




= (0.071 ± 0.002Pa ·ml
Hz2 · g
). (12)
Using this value of a0, then, one can use Eq. (1) with the known
mass density of the sample and the measured f0 to compute
the CEM. The total CEM measurement uncertainty (accuracy)
depends upon the error in a0 and fitting error for f0 for the
data scan. In practice, we find that the fitting error for f0 is
typically ∼0.2%, which is considerably smaller than that from
the calibration constant, which is 2.8%.
C. Device precision
One of the advantages of RASOV over non-resonant
methods such as TEG is the improved measurement precision.
To investigate this precision, Fig. 5 shows a box-and-whisker
plot of repeated measurements of two low-concentration
agarose gels as samples with CEM similar to blood clots.
FIG. 5. Box-and-whisker plot of consecutive RASOV measurements of
elasticity of a 3.06 mg/ml agarose gel (left with blue data circles) and a
3.62 mg/ml agarose gel (right with red data triangles). Measurement times
were within a window of 18 min (left) and 12 min (right). The bottom,
middle, and top solid lines of each box are defined by the first (25%),
middle (50%), and third quartiles (75%) of corresponding data distribution.
Horizontal dashed lines across the boxes are mean values of elasticity.
The repeated measurements of a 3.06 mg/ml agarose gel (17
consecutive measurements 2.66 ± 0.04 kPa) and a 3.62 mg/ml
agarose gel (30 consecutive measurements 4.63 ± 0.04 kPa)
suggested a precision on the order of 1%–2%. In comparison,
our previous study showed that RASOV offered a measure-
ment precision of ∼5% in whole blood samples, compared to
∼10% via TEG. While the precision when measuring whole
blood may be expected to be higher than that of agarose, as
we will show below, we find that accuracy is a greater concern
than precision when measuring plasma samples. This finding
illustrates that RASOV is capable of CEM measurements with
high repeatability.
D. Heparin study
One potential application for CEMport is monitoring of
the level of blood anticoagulants, which can aid in reduc-
ing post-operative complications. Heparin is a widely used
anticoagulant that is intravenously administered before and
during heart surgery. Here, we study the effect of heparin on
CEM as measured by the CEMport. Fig. 6 illustrates the CEM
of clots formed by NPP as a function of heparin concentra-
tion. There is a clear trend of decreasing CEM with increased
heparin concentration, with a rapid transition between high
(>500 Pa) and low (<350 Pa) CEM as the heparin concentra-
tion increased from 0.025 to 0.050 U/ml. At heparin concentra-
tions above 1.8 U/ml, the samples were palpably less solid and
the microbead transducer was more difficult to position. Above
4.0 U/ml, clots failed to form during the 2-3 h waiting period.
This time-point was specifically chosen based on indications in
the literature that both structural and viscoelastic steady-state
will reach completion by approximately 2 h.39,40
Importantly, the values we previously measured for CEM
in whole blood clots (∼1.5–5.0 kPa)26 and presently in NPP
clots (552 ± 74 Pa) via RASOV are consistent with TEG
measurements performed in whole blood (∼1.5–5.0 kPa)26
and plasma (423 ± 24 Pa as inferred from the reported data,
recognizing that different sources of plasma may have different
baseline CEM).41 The significantly higher value of CEM for
whole blood compared to NPP can be partially explained by
the presence of red blood cells and platelets in the whole
blood.33 Moreover, there is a wide variation in blood compo-
nents encountered in normal and pathological conditions such
FIG. 6. CEMport measurements of normal platelet-poor plasma (NPP) ver-
sus heparin concentration. The inset displays a magnified view up of low
concentrations on a linear scale to include the zero concentration data point.
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as thrombocytopenia and anemia. The literature suggests
CEM ranges of 0.3 kPa–1.9 kPa and 2.3 kPa–4.4 kPa as a con-
sequence of platelet and hematocrit variation, respectively.33
These wide variations suggest the role of devices to more
precisely profile platelet and red blood cell contributions to
clot quality and consequently thrombotic disorders.
The precision (repeatability) for measurements obtained
for individual control plasma samples was 1.2%. When aver-
aging across 2 samples on 2 different days, the standard devi-
ation increased to 12%. Thus, CEMport measurements of a
single sample of NPP exhibit similar precision as that observed
for agarose in Fig. 5. At the same time, the larger variability
observed on different days suggests that there is some vari-
ability in the plasma itself, in the amount of time elapsed
between preparing the clot and measurement (which was be-
tween 2 and 3 h), or in the mixing procedure to form a clot.
Importantly, the range of heparin concentrations em-
ployed here is physiologically relevant when compared with
the circulating concentration of heparin observed in human
patients after heparin administration. During cardiopulmonary
bypass surgery, the concentration of heparin in whole blood
was found to range from 2 to 4 U/ml,42 which constitutes a
highly anticoagulated state, consistent with our finding that
NPP is difficult to clot above 1.8 U/ml and fails to clot above
4.0 U/ml. Heparin facilitates the antithrombin-mediated inac-
tivation of thrombin which limits the conversion of fibrinogen
to fibrin and alters the integrity of the fibrin fiber matrix
during clot formation.43 The mechanical properties of blood
clots are strongly dictated by the fibrin matrix, in addition
to red blood cells and platelets.1,33,44 We previously found
using RASOV that the CEM of purified fibrin clots increases
as the square of the fibrinogen concentration. At the same
time, reducing the thrombin concentration was associated with
reduced CEM due to incomplete conversion of free fibrinogen
into fibrin.26 In whole blood, CEM was similarly reduced
with increased concentration of low molecular weight heparin
(as measured via antifactor Xa activity), while there was a
positive correlation of antifactor Xa with thrombin generation
time.45 These previous observations are consistent with the
observed trend in Fig. 6 of decreasing CEM with increasing
heparin concentration, even at concentrations significantly
below 1.8 U/ml where stable clots form.
Interestingly, the CEMport exhibited rapid CEM changes
with heparin at exceedingly low concentrations of<0.05 U/ml,
concentrations for which anticoagulation is not normally
observed and measurements of heparin using antifactor Xa
are difficult. This feature may be particularly relevant to post-
surgical monitoring. Typically, protamine is administered after
surgery to neutralize heparin and reverse the effects of anti
coagulation. In this scenario, it has been found that plasma
heparin concentrations can rise post-operatively to levels as
high as 0.18 U/ml.12 This heparin rebound effect poses possible
risks of post-operative bleeding, which can increase morbidity
and mortality.46 The use of the CEMport may therefore aid
in detecting low concentrations of heparin that reappear after
protamine therapy in order to mitigate such risks. A patient-
specific CEM baseline could be established before surgery and
protamine dosage adjusted to re-establish the baseline post-
surgically. While the study here focused on plasma, future
studies in whole blood may translate to a simple protocol for
blood sampling in this clinical scenario.
IV. CONCLUSION
We have introduced for the first time a portable microelas-
tometry device, CEMport, specifically designed for blood clot
analysis using RASOV. RASOV associates the elastic modulus
to the intrinsic mechanical resonance of a sample clotted inside
a fixed dimension microwell. RASOV provides a resonant
signal with inherently high signal-to-noise in comparison to
single frequency techniques or free-oscillation methods such
as the torsion pendulum. In this paper, we have fully developed
the measurement principles and motivated the design of the
microbead transducer to accurately measure CEM over the
typical range of blood and plasma samples. These design
metrics can be used as a template to construct RASOV-based
elastometers tailored for other application spaces, such as soft
tissues, where conventional mechanical analyzers often lack
the force sensitivity needed to accurately measure elasticity.
We have described the construction and performance of
the CEMport, the first portable RASOV-based device. The
CEMport offers a large improvement in displacement dynamic
range by employing a commercial displacement sensor, which
leads to a large range of resonant strain amplitudes over
which accurate CEM is obtained. Other improvements include
mitigating the effects of sample dehydration by employing a
humidified chamber, semi-automating the RASOV data fitting,
and providing a user-friendly interface to rapidly obtain the
CEM value. We have calibrated the system via a commercial
mechanical analyzer (R2 > 0.998) and have demonstrated the
system precision (repeatability) when measuring biogels (1%-
2%) and plasma (1.2%). Importantly, the CEMport maintains
low strain dynamics which affords insight into the perturba-
tive, linear viscoelastic properties of clots. Some challenges
remain to streamline the CEMport operation. Manual voltage
adjustments to the transducer are sometimes required to adjust
the unknown sample’s resonant vibration amplitude within the
CEMport dynamic range, and this process could be automated.
The need for manual bead placement and to scan to locate the
bead by the displacement sensor adds time to the otherwise
4 s measurement procedure. We acknowledge that the current
2-3 h waiting period allowed for clot formation may overes-
timate the time needed to achieve maximum clot density, and
most certainly, this time frame limits the device in its present
state to research-based applications. However, with the newly
introduced portability, accuracy, and precision advancements
presented here, future efforts focusing on optimizing clotting
times significantly shorter than 2-3 h, as well as improve-
ments to the bead scanning algorithm, will allow us to begin
considering CEMport use within a clinical setting such as
operating rooms for real-time CEM measurements during and
after surgery.
While the focus of this study was to quantify the elastic
modulus (i.e., storage modulus), we expect that the damp-
ing factor, γ0, in Eq. (4) can similarly be related to the loss
modulus using RASOV. Damping factor values were tabulated
as part of the fitting routine in this study; however, we note
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that additional effort with a validating technique is needed to
determine the accuracy of the values obtained in this way. Our
preliminary efforts suggest that γ0 has a similar trend as f0 as
a function of heparin concentration, so it remains to be seen
whether damping can provide significant new insight into clot
mechanics.
The development of a reliable and accurate microelastom-
etry device creates legitimate opportunities within the clinical
space that can directly impact the decision-making capabilities
of surgical care. Current CEM testing modalities are limited
by poor standardization, low diagnostic sensitivity, and poor
repeatability. Importantly, this study shows that the CEMport
exhibits high sensitivity to small plasma levels of heparin
which are normally difficult to measure. This provides prom-
ising evidence to suggest that the CEMport may be useful for
discerning heparin rebound following protamine administra-
tion after cardiac surgery. Other potential applications for the
CEMport include monitoring treatments for hemophilia to aid
in drug dosing, differentiating clot quality in stored blood prod-
ucts,47 potentially diagnosing cardiovascular diseases such as
CAD before symptomatic onset,1 and providing hemostasis
therapy guidance in traumatic coagulopathies.9
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